)
Lupin Limited through its subsidiary Lupin Pharmaceuticals Inc, has launched its duloxetine 40 mg delayed-release (DR) capsule, which is the first and only generic duloxetine formulation to become available in 40 mg dosage strength. “Lupin is excited to bring this new strength to market, as it adds to the currently-available dosing options for greater flexibility of treatment,” said Lupin in a press release.
Lupin is the only generic manufacturer to offer all duloxetine dosage strengths – the 20 mg, 30 mg, 60 mg, and now the newest 40 mg. Lupin’s generic duloxetine 40 mg DR capsules are therefore the first and only capsule available for patients in this dosage strength.
Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) developed by Eli Lilly and marketed under Cymbalta brand, is mostly prescribed for major depressive disorder, generalised anxiety disorder, fibromyalgia and neuropathic pain.
According to IMS MAT June 2015 data, Cymbalta delayed-release capsules 20 mg, 30 mg and 60 mg strengths had annual US sales of approximately $ 1.05 billion.
